Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis

Basic Details
Date Posted
Thursday, November 10, 2022
Status
In progress
Medical Product
Ozempic (semaglutide)
Description

This analysis performed signal identification for Ozempic (a specific form of semaglutide) by monitoring non-pregnancy and non-cancer outcomes among new users of Ozempic compared to new users of sitagliptin among type 2 diabetics.

The study period includes data from January 1, 2018 to February 28, 2022.

The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.

Deliverables (1)
Sentinel Analytic Package: Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis
Additional Details
FDA Center
CDER
Time Period
January 1, 2018 – February 28, 2022
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
Individuals 18 years of age and older with evidence of type 2 diabetes
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Ozempic (semaglutide) & Signal Identification